Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center Academic Article uri icon

Overview

MeSH Major

  • Carcinoma
  • Lymph Nodes
  • Neoplasms, Glandular and Epithelial
  • Ovarian Neoplasms

abstract

  • Among AJ patients found to have a pathogenic mutation on genetic assessment, approximately 22.8% had a mutation that would be missed with BRCA1/2 AJ founder mutation testing. Comprehensive multigene panel sequencing can provide clinically relevant genetic information for AJ patients and should be considered for genetic assessment in this population.

publication date

  • March 2019

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.31856

PubMed ID

  • 30480775

Additional Document Info

start page

  • 690

end page

  • 697

volume

  • 125

number

  • 5